Report Overview

The global Angelman Syndrome drugs market size is USD xx billion in 2019 and projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

People suffering from Angelman syndrome generally tend to live a normal life span, but the disorder cannot be cured. Angelman syndrome is caused due to the absence of a functional copy of the UBE3A gene, which is inherited from the mother. It is also estimated that, over the forecast period, the Angelman syndrome treatment market will witness a moderate growth. Recently, the U.S. Food and Drug Administration has approved orphan drug GTX-101 for the treatment of Angelman syndrome. Treatment mainly focuses on managing the medical and developmental issues. Currently, there is no specific treatment therapy for Angelman syndrome, but available treatment options are focusing on seizure control. Physical, communication, behavioural, and other therapies are useful in developing the maximum potential in an individual suffering from Angelman syndrome. The hospital service providers segment is expected to contribute maximum market share in the global Angelman syndrome treatment market. Angelman syndrome treatment majorly focuses on the improvement of a patients symptoms.



Market Drivers

The Angelman syndrome treatment market is expected to grow over the forecast period, due to increasing research activities and R&D expenditure. Government initiatives in developing new treatment options for Angelman syndrome are expected to drive the growth of the global Angelman syndrome treatment market over the forecast period 2019-2028. Furthermore, the effectiveness of the treatment by reducing the effect of the symptoms is also driving the growth of the global Angelman syndrome treatment market. Improvements in the healthcare sector are further facilitating the growth of the Angelman syndrome treatment market, globally